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Abstract
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by immune dysregulation
due to a defect in lymphocyte apoptosis. The clinical manifestations may be noted in multiple
family members and include lymphadenopathy, splenomegaly, increased risk of lymphoma and
autoimmune disease, which typically involve hematopoietic cell lines manifesting as multilineage
cytopenias. Since the disease was first characterized in the early 1990s, there have been many
advances in the diagnosis and management of this syndrome. The inherited genetic defect of many
ALPS patients has involved (FAS) pathway signaling proteins, but there remain those patients
who carry undefined genetic defects. Despite ALPS having historically been considered a primary
immune defect presenting in early childhood, adult onset presentation is increasingly becoming
recognized, and more so in genetically undefined patients and those with somatic FAS mutations.
Thus, future research may identify novel pathways and/or regulatory proteins important in
lymphocyte activation and apoptosis.
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Introduction
Autoimmune lymphoproliferative syndrome (ALPS) is a disease characterized by immune
dysregulation due to an inability to regulate lymphocyte homeostasis through abnormalities
in lymphocyte apoptosis or programmed cell death. This defect leads to a
lymphoproliferative disease with clinical manifestations that can include lymphadenopathy,
hepatomegaly, splenomegaly, increased risk of lymphoma, and autoimmune diseases
(typically involving hematopoietic cell lines). The signature laboratory abnormalities in
ALPS include an expansion of T cells that express the alpha/beta T cell receptor but lack
both CD4 and CD8 in peripheral blood and tissue samples (double negative T cells, DNTs).
Other characteristic laboratory findings include elevated levels of interleukin-10, vitamin
B12, and defective Fas-mediated apoptosis in vitro. In two-thirds of the cases, the genetic
defect in the FAS gene has been established; however, in many cases, it remains undefined.
Epidemiology and Pathogenesis
There have been nearly 500 patients originating from more than 300 families identified with
ALPS[1]; however, the true incidence and prevalence remains unknown, as many patients
remain undiagnosed or misdiagnosed. The disease has been reported in various racial and
ethnic backgrounds, and some reports have suggested a male preponderance.
The pathogenesis of ALPS in the majority of patients results from defective apoptosis of
lymphocytes mediated through the Fas/Fas ligand (FasL) pathway[2]. Thus, a defect in this
pathway leads to expansion of lymphocytes, including self antigen-specific populations, and
subsequent autoimmunity. Fas is also thought to play a role in suppression of malignant
transformation of lymphocytes, and indeed, ALPS patients carry an increased risk of
lymphoma[3]. The pathogenesis remains an ongoing topic of research.
Approximately two thirds of ALPS patients have an identified genetic defect in the FAS
(Table 1). A germline mutation in FAS is the most commonly identified genotype at this
time[2]. Others may acquire a somatic mutation in FAS limited to the DNT cells [4]. Other
proteins involved in the Fas mediated apoptosis pathway have also been implicated in some
patients, including defects in the genes encoding Fas ligand (FASL)[5] and caspase 10[6, 7].
A large number of patients who meet the diagnostic criteria for ALPS have undefined
genotypes.
The recent awareness of delayed presentations of the disease has led to an increased
diagnosis in older patients who might have otherwise been given an alternative diagnosis[8–
10]. Many of these patients have had a more indolent course and may have developed their
initial symptoms during childhood with either diagnosis delayed due to unusual clinical
manifestations, late referral to a tertiary center, or late onset disease due to somatic
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mutations in Fas. Additionally, there have been at least seven individuals identified who
carried the germline FAS mutation (inherited heterozygotes), were initially asymptomatic,
and at some point they were thought to have had a somatic genetic event in the second allele
encoding FAS, leading to the clinical symptoms[11].
Clinical Manifestations
The earliest and most common clinical manifestation of ALPS is chronic lymphadenopathy
and/or splenomegaly, which have been asymptomatic and incidentally identified during
routine physical examinations. ALPS patients can also have multilineage cytopenias that are
chronic and can be refractory to therapy. This has generally been thought to be most severe
in early childhood, as this is the age at which there is expansion of the lymphocyte
repertoire, albeit adults have presented with this as well. ALPS patients may present initially
with episodes of fatigue, pallor, and icterus due to hemolytic anemia. They may also develop
easy bruising and mucocutaneous bleeding due to thrombocytopenia. Bacterial infections
can occur due to neutropenia. There is also potential for developing multiple autoimmune
problems of other organs including liver, kidneys, and eyes or of lymphoproliferative
disorders involving many different organ systems [12], which may be confused with atypical
presentations of systemic lupus erythematosus since anti-nuclear-antibodies (ANA) are not
uncommon.
The most common laboratory abnormalities found are cytopenias due to autoimmune
destruction or splenic sequestration. Conversely, eosinophilia and monocytosis may also be
associated findings[13]. Autoantibodies may be present and include positive Coomb’s direct
antiglobulin test, rheumatoid factor (RF), or anti-nuclear antigen (ANA).
Hypergammaglobulinemia is also frequently present[12]. Serum IL-10, soluble FAS ligand,
and vitamin B12 are commonly elevated in ALPS patients with FAS mutations and can be
useful biomarkers[14, 15] for these patients, but may not be abnormal in those with
unidentified genetic mutations. Although not commercially available, flow cytometry of the
blood for increased number of DNTs can be performed and is pathognomonic of ALPS.
Diagnosis and Differential Diagnosis
In 2009, an international consensus conference was held, and a revised set of diagnostic
criteria was published in 2010 (Table 2) [16]. Based on this set of criteria, definitive
diagnosis is based on the presence of two required criteria and one primary accessory
criterion. A probable diagnosis is based on the presence of both required criteria plus one
secondary accessory criterion.
Revised criteria eliminate the lymphocyte apoptosis assay as a required criterion, as it has
been found to be a resource intensive assay to perform and may only be available at select
centers. Methodology of this assay also varies across centers, leading to variable results. The
revised criteria also take into account genetic information and other biomarkers which have
been shown to be supportive of a diagnosis of ALPS[14]. These secondary accessory criteria
provide additional features that may help to support a diagnosis, even when both primary
criteria may not be met. Overall, this revision of the diagnostic criteria facilitates the
diagnosis of ALPS, particularly in patients who may present at an older age or in an atypical
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fashion due to somatic or successive and cumulative mutations. Increasingly recognized are
later presentations of ALPS, in part due to the revised set of diagnostic criteria. A case
report was published in 2011 which described a 50 year old man who presented with the
clinical syndrome of cytopenias, lymphadenopathy, was found to have elevated DNTs, and
diagnosed with probable ALPS[17].
ALPS should be considered as a differential diagnosis due to variable phenotypes that
overlap with other syndromes, such as Evans’ syndrome, hemophagocytic
lymphohistiocytosis (HLH), Castleman’s disease, and other lymphoproliferative
disorders[10]. Diligent review of family history in both children and adults is helpful in
making the diagnosis of a rare inherited genetic disorder like ALPS.
Treatment
Overall, the management of ALPS focuses on treatment of the primary disease
manifestations and complications since a cure for the genetic defect is presently not
possible. The bulk of management focuses on treating disease specific complications,
including lymphoproliferation and autoimmune cytopenias with immunosuppression.
The initial therapy for autoimmune multilineage cytopenias is similar to that of other
immune mediated chronic and persistent cytopenias. Initial therapy involves high dose
corticosteroids +/− intravenous immune globulin (IVIG). High-dose pulse therapy with
intravenous (IV) methylprednisolone (starting at 5–10 mg/kg, though doses up to 30 mg/kg
have been used), followed by low dose oral prednisone (1–2 mg/kg) maintenance therapy
has been successful in many patients. IVIG is generally given concomitantly with pulse dose
methylprednisolone at doses of 1–2g/kg [1]. Other steroid sparing agents that have been
trialed in ALPS include rituximab[18, 19], mycophenolate mofetil (MMF)[20], and
mammalian target of rapamycin (mTor) inhibitors such as sirolimus[21, 22]. Pentostatin has
also been used with success in some children with refractory cytopenias[23].
The use of MMF was first described in 2005 by Rao et al. MMF is a prodrug of
mycophenolic acid, which is a reversible inhibitor of inosine monophosphate dehydrogenase
(IMPDH) in purine (guanine) biosynthesis that is ultimately necessary for the growth of both
T and B cells. Thus, suppressing T and B cells limits autoimmune destruction of healthy
cells. MMF has been used in various autoimmune disorders, including psoriasis, systemic
lupus as well as autoimmune cytopenias[24]. With regards to ALPS, MMF has been used
successfully as a steroid-sparing agent in more than 50 cases, and is most commonly used to
treat autoimmune manifestations such as cytopenias [20, 25]. MMF is usually given
concomitantly with high dose IV corticosteroids initially, and then continued while tapering
oral prednisone, with an overlap of at least 2 weeks in order to allow MMF to achieve
therapeutic levels. MMF has also been used for other autoimmune complications of ALPS,
including uveitis, glomerulonephritis, hepatitis and autoimmune infiltrative pulmonary
disease.
Sirolimus has also been used successfully to treat refractory cytopenias, as well as other
autoimmune manifestations of ALPS in those failing initial corticosteroids and IVIG. In
2009, Teachey et. al described four patients treated for autoimmune cytopenias, all with
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excellent response, as well as two patients treated for autoimmune arthritis and colitis who
demonstrated marked improvement in their clinical severity. In addition, three of these
patients had resolution of adenopathy and splenomegaly, and all had a reduction in their
DNTs[21]. Thus, mTor inhibitors may be a good option for patients who fail corticosteroids,
MMF, and present with massive adenopathy and splenomegaly leading to cytopenias.
Pentostatin has been used by some to treat patients with refractory cytopenias. Bajwa et. al.
[23] described a case of ALPS presenting at birth that was refractory to splenectomy and
immunosuppressive therapy, but responded to pentostatin followed by hematopoietic stem
cell transplantation.
Rituximab has been used in many autoimmune diseases, including autoimmune hemolytic
anemia and idiopathic thrombocytopenic purpura[26]. There has been controversy regarding
its use in ALPS, as it has been noted to cause a permanent hypogammaglobulinemia
requiring replacement therapy in some patients and unsustained benefits in others. Rao et. al.
[18] described the use of rituximab in twelve ALPS patients. In seven out of nine patients
with ALPS and autoimmune thrombocytopenia, rituximab led to a median response duration
of 21 months. However, none of the 3 children treated with rituximab for autoimmune
hemolytic anemia (AIHA) responded. Toxicities included profound and prolonged
hypogammaglobulinemia in three patients requiring IVIG, total absence of antibody
response to polysaccharide vaccines lasting up to 4 years after rituximab infusions in one
patient, and prolonged neutropenia in one patient. Thus, given risks of additional
immunosuppression, rituximab is reserved for cases in which alternative
immunosuppressants have failed, and in whom thrombocytopenia seems to be a
predominant factor.
Many ALPS patients have been treated with splenectomy in the past to manage chronic,
refractory cytopenias, but this is currently not advised[1, 27]. Unfortunately, many patients
have had relapse of their cytopenias after splenectomy. However, even more concerning, is
that some have had fatal infections, including pneumococcal sepsis. In patients who have
had splenectomy prior to their diagnosis, it is recommended that they remain on long-term
antibiotic prophylaxis and maintain their vaccinations. In known ALPS cases, splenectomy
should only be reserved for patients who have failed all other medical therapies and continue
to have life threatening cytopenias that are felt to be due to splenic sequestration. It is
imperative to note that more than 50% of the ALPS patients have had their cytopenias
relapse after splenectomy proving it to be a futile exercise that only increases their risk of
pneumococcal sepsis[27]. Partial splenectomy or splenic embolization should also be
considered in these patients as an alternative to complete splenectomy[28].
Other treatments may be on the horizon as we learn more about the molecular mechanisms
underlying the clinical manifestations in ALPS. For example, in vitro, IL-17 has been found
to inhibit Fas-induced cell death[29]. IL-17 neutralization seems to improve lymphocyte
apoptosis with ALPS. Treatment with anti-IL-17A antibodies has been shown to ameliorate
the autoimmune manifestations and the lymphoproliferative phenotype and prolongs
survival in a mouse model of ALPS.
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The only curative therapy for ALPS at this time is hematopoietic stem cell transplantation
(HCT). Indications for transplant include lymphoma, severe and recalcitrant autoimmune
cytopenias, and patients with severe disease phenotype (generally those with homozygous
and compound heterozygous FAS defects)[30–32]. However, experience with stem cell
transplantation in ALPS is extremely limited with only a few published case reports, and
long-term outcomes are yet to be determined. As expected, some cases have been
complicated by post-transplant infections as well as graft versus host disease. In one case, a
14-year-old boy with ALPS, lymphoma, and subsequent histiocytic sarcoma underwent a
mismatched unrelated donor transplant, complicated by GVHD, methicillin-resistant
Staphylococcus aureus pneumonia, and pulmonary hemorrhage, and ultimately he died after
three months owing to these complications[33].
In addition to autoimmune disease, ALPS patients have a well-established risk for
lymphoma. In cohort of 150 ALPS-FAS patients, 18 patients developed lymphoma and 1
patient another hematopoietic malignancy. When compared to the general population, these
patients have a highly significant observed to expected ratio of hematopoietic malignancy
[28].
Although there is a risk of lymphoma and life-threatening cytopenias [28], many patients
with ALPS, and particularly those with FAS mutations, have their lymphadenopathy
decrease over time, and autoimmune complications remain manageable with limited steroid
sparing immunosuppression using mycophenolate mofetil and sirolimus. Estimated survival
for ALPS-FAS has been reported to be near 85% by age 50, compared to healthy non-ALPS
individuals who have an expected survival of 93–95% by age 50. Since many of the recently
diagnosed ALPS patients are still children or adolescents, they will need to be studied long-
term to determine a more accurate prognosis, risk of lymphoma, and life expectancy.
Conclusions
Autoimmune lymphoproliferative syndrome is a complex disease that now includes patients
that may not have been previously recognized. We have learned that onset can be in
adulthood and without family history due to somatic mutations, or accumulation of multiple
mutations. Many options for management of refractory autoimmune complications have
been described, and there is continued research being conducted regarding outcomes in these
patients. Further study of ALPS patients and the discovery of previously undefined genetic
defects may provide additional insight into immune cell regulation via apoptotic pathways
and its role in health and disease.
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Table 2
Current clinical criteria for the diagnosis of ALPS
2010 criteria
Required criteria
Chronic (> 6 months), nonmalignant, noninfectious lymphadenopathy or splenomegaly or both
Elevated CD3+TCRαβ+CD4−CD8− DNT cells (≥ 1.5% of total lymphocytes or 2.5% of CD3+ lymphocytes) with normal or elevated
lymphocyte counts
Accessory: Primary
Defective lymphocyte apoptosis (2 separate assays)
Somatic or germline mutation in FAS, FASLG, or CASP10
Accessory: Secondary
Elevated plasma sFASL levels (>200 pg/mL) OR elevated plasma interleukin-10 levels (>20 pg/mL) OR elevated serum or plasma vitamin B12
levels (> 1500 ng/L) OR elevated plasma interleukin-18 levels > 500 pg/mL
Typical immunohistological findings as reviewed by an experienced hematopathologist
Autoimmune cytopenias (hemolytic anemia, thrombocytopenia, or neutropenia) AND elevated immunoglobulin G levels (polyclonal
hypergammaglobulinemia)
Family history of a nonmalignant/noninfectious lymphoproliferation with or without autoimmunity
FASLG – FAS ligand gene; CASP10 – Caspase-10 gene; sFASL – soluble FAS ligand
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